Abstract

Recently reported decameric vanadate (V 10) high affinity binding site in myosin S1, suggests that it can be used as a tool in the muscle contraction regulation. In the present article, it is shown that V 10 species induces myosin S1 cleavage, upon irradiation, at the 23 and 74 kDa sites, the latter being prevented by actin and the former blocked by the presence of ATP. Identical cleavage patterns were found for meta- and decavanadate solutions, indicating that V 10 and tetrameric vanadate (V 4) have the same binding sites in myosin S1. Concentrations as low as 50 μM decavanadate (5 μM V 10 species) induces 30% of protein cleavage, whereas 500 μM metavanadate is needed to attain the same extent of cleavage. After irradiation, V 10 species is rapidly decomposed, upon protein addition, forming vanadyl (V 4+) species during the process. It was also observed by NMR line broadening experiments that, V 10 competes with V 4 for the myosin S1 binding sites, having a higher affinity. In addition, V 4 interaction with myosin S1 is highly affected by the products release during ATP hydrolysis in the presence or absence of actin, whereas V 10 appears to be affected at a much lower extent. From these results it is proposed that the binding of vanadate oligomers to myosin S1 at the phosphate loop (23 kDa site) is probably the cause of the actin stimulated myosin ATPase inhibition by the prevention of ATP/ADP exchange, and that this interaction is favoured for higher vanadate anions, such as V 10.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.